Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$16.11M+2207.45%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua R. Disbrow
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 83
- Beta
- 0.27
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -4.23
Financials
Revenue
$16.11M+2207.4%Net Income
$-15.0KEBITDA
$-777.0KFree Cash Flow
—EPS (diluted)
$0.50Shares Outstanding (diluted)
12.32M+19553577.8%Operating Expenses
$10.43MCash & Debt
$26.31MRevenue by Segment (annual)
$15.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $57.57M | $-14.25M | $-1.16 |
| 2025 | $66.38M | $-13.56M | $-2.16 |
| 2024 | $65.18M | $-15.84M | $-2.86 |
| 2023 | $107.40M | $-17.05M | $-5.11 |
| 2022 | $96.67M | $-108.78M | $-74.01 |
| 2021 | $65.63M | $-58.29M | $-69.60 |
| 2020 | $27.63M | $-13.62M | $-60.20 |
| 2019 | $7.32M | $-47.17M | $-1210.28 |
| 2018 | $3.66M | $-10.19M | $-3061.23 |
| 2017 | $3.22M | $-22.51M | $-193194.38 |
| 2016 | $2.56M | $-28.18M | $-1294738.36 |
| 2015 | $261.8K | $-7.72M | $-551671.71 |
| 2014 | $58.9K | $-5.58M | $-619854.44 |
| 2013 | $1.8K | $-57.3K | $-7164.75 |
Valuation
AYTUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (2)
- Newsaccessnewswire.com·5h ago·Positive
…bcast today, September 22, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 full year and fourth quarter.
View source ↗ - Newsaccessnewswire.com·6d ago·Neutral
…er Operational and Financial Results on September 22, 2026 DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has …
View source ↗
Earnings
Tue, Sep 22(date passed)
Consensus estimate $-0.29 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, May 13$-0.53 vs $-0.31miss
- Tue, Feb 3$-1.05 vs $-0.26miss
- Thu, Nov 13$-0.08 vs $-0.06miss
- Tue, Sep 23$-2.92 vs $-0.02miss
- Wed, May 14$0.20 vs $-0.17beat
- Wed, Feb 12$-0.28 vs $-0.28beat
Estimates and results for AYTU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AYTU officers and directors.
- Bought
- $316k
- Sold
- —
10 trades
0 trades
- Disbrow Jarrettbought
- Disbrow Joshua R.bought
- Nantahala Capital Management, Llcbought
- Disbrow Joshua R.bought
- Pyszczymuka Gregbought
- Disbrow Joshua R.bought
- Disbrow Joshua R.bought
- Pyszczymuka Gregbought
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AYTU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.